Payment overview · 2025
General Payments
$619.81
25 reported records · 14 companies
Healthcare provider profile · identity verified
Jon M Hall, MD
Allopathic & Osteopathic Physicians|Family Medicine · NEWBURGH, IN · NPI 1184723975
Verified facts
What the public records show
CMS Open Payments records show Jon M Hall, MD received $619.81 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $208.54 | 33.6% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $105.32 | 17.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.94 | 10.5% | 3 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $46.43 | 7.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.88 | 5.5% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $25.36 | 4.1% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.16 | 3.4% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $21.00 | 3.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.18 | 2.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.35 | 2.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.98 | 2.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.34 | 2.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.48 | 2.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.85 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $619.81 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $195.75 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $105.32 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $64.94 | 3 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $46.43 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.88 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.88 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $25.36 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $12.79 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $12.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 330 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 315 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 278 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 234 | 45 |
| Lisinopril | Lisinopril | 209 | 48 |
| Alprazolam | Alprazolam | 181 | 25 |
| Gabapentin | Gabapentin | 162 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 161 | 22 |
| Omeprazole | Omeprazole | 134 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 32 |
| Clonazepam | Clonazepam | 111 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 29 |
| Montelukast Sodium | Montelukast Sodium | 103 | 11 |
| Allopurinol | Allopurinol | 95 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 13 |
| Furosemide | Furosemide | 87 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 12 |
| Levetiracetam | Levetiracetam | 81 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 79 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 78 | suppressed |
| Metformin Hcl | Metformin Hcl | 77 | suppressed |
| Glimepiride | Glimepiride | 76 | 16 |
| Meloxicam | Meloxicam | 76 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 75 | suppressed |
| Baclofen | Baclofen | 73 | suppressed |
| Ondansetron Odt | Ondansetron | 72 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 19 |
| Jardiance | Empagliflozin | 71 | 13 |
| Losartan Potassium | Losartan Potassium | 71 | 22 |
| Metformin Hcl Er | Metformin Hcl | 71 | 22 |
| Diazepam | Diazepam | 70 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 17 |
| Pregabalin | Pregabalin | 68 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 64 | suppressed |
| Lorazepam | Lorazepam | 61 | 15 |
| Trazodone Hcl | Trazodone Hcl | 61 | 14 |
| Promethazine Hcl | Promethazine Hcl | 57 | 11 |
| Valsartan | Valsartan | 57 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 56 | suppressed |
| Bupropion Xl | Bupropion Hcl | 55 | suppressed |
| Bumetanide | Bumetanide | 53 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 53 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | suppressed |
| Potassium Chloride | Potassium Chloride | 47 | suppressed |
| Atenolol | Atenolol | 46 | suppressed |
| Fluconazole | Fluconazole | 45 | 12 |
| Prednisone | Prednisone | 44 | 16 |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | suppressed |
| Mirtazapine | Mirtazapine | 40 | 12 |
| Simvastatin | Simvastatin | 40 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 39 | 13 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 29 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $619.81 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Andembry, Azstarys, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, Dyanavel XR, EVENITY, FANAPT, FARXIGA, HETLIOZ, JOURNAVX, NURTEC ODT, Ozempic, REXULTI, Rybelsus, VRAYLAR, XIFAXAN, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error